441 results on '"Copelan, E."'
Search Results
2. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome
3. Racial differences in allogeneic hematopoietic cell transplantation outcomes among African Americans and whites
4. Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation
5. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation
6. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
7. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
8. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience
9. Leukemia cell mobilization: a road to eradication?
10. Hematopoietic cell transplantation in MDS: undervalued and underutilized
11. Quality of life and outcomes in patients ≥ 60 years of age after allogeneic hematopoietic cell transplantation
12. Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study
13. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis
14. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
15. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
16. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
17. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
18. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation
19. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
20. BU- vs TBI-based conditioning for adult patients with ALL
21. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia
22. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT
23. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation
24. Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?
25. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
26. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
27. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation
28. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
29. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease
30. Apheresis days required for harvesting CD34 + cells predicts hematopoietic recovery and survival following autologous transplantation
31. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation
32. Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein–Barr virus DNA PCR
33. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation
34. Diffuse alveolar hemorrhage following gemtuzumab ozogamicin
35. Exploring Cost Savings of a Modified Plerixafor Protocol for Use in Autologous Stem Collection
36. Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study
37. PSY106 - Exploring Cost Savings of a Modified Plerixafor Protocol for Use in Autologous Stem Collection
38. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
39. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
40. Validating the positive impact of in-hospital lay care-partner support on patient survival in allogeneic BMT: a prospective study
41. Predictive Factors for Adverse Outcomes After Use of Donor Cell Infusion (DCI) in Patients with Relapsed Hematological Malignancies Treated with Allogeneic Hematopoietic Cell Transplantation (alloHCT)
42. The Role of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) in Autologous Stem Cell Transplantation for Multiple Myeloma
43. Immunogenicity of Polysaccharide Pneumococcal Vaccination in Autologous Hematopoietic Stem Cell Transplantation
44. The Impact of the Major Histocompatibility Complex Class I-Related Chain a (Mica) and Human Leukocyte Antigen (HLA)-DP Mismatches on Severe Acute GVHD in Patients Receiving Allogeneic Hematopoietic Progenitor Cell Transplants (AHPCT) from Adult Unrelated Donors
45. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
46. Influence of type of antecedent disorder on outcome of therapy-related AML.
47. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
48. Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia
49. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
50. Killer-Immunoglobulin-Like Receptor (KIR) Gene Polymorphism and BKV Associated Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplant Recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.